Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
Identifieur interne : 002213 ( Main/Exploration ); précédent : 002212; suivant : 002214Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
Auteurs : Paolo A. Ascierto [Italie] ; Grant A. Mcarthur [Australie] ; Brigitte Dréno [France] ; Victoria Atkinson [Australie] ; Gabrielle Liszkay [Hongrie] ; Anna Maria Di Giacomo [Italie] ; Mario Mandalà [Italie] ; Lev Demidov [Russie] ; Daniil Stroyakovskiy [Russie] ; Luc Thomas [France] ; Luis De La Cruz-Merino [Espagne] ; Caroline Dutriaux [France] ; Claus Garbe [Allemagne] ; Yibing Yan [États-Unis] ; Matthew Wongchenko [États-Unis] ; Ilsung Chang [États-Unis] ; Jessie J. Hsu [États-Unis] ; Daniel O. Koralek [États-Unis] ; Isabelle Rooney [États-Unis] ; Antoni Ribas [États-Unis] ; James Larkin [Royaume-Uni]Source :
- The Lancet. Oncology [ 1474-5488 ] ; 2016.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Azétidines (administration et posologie), Femelle, Humains, Indoles (administration et posologie), Jeune adulte, Marqueurs biologiques tumoraux (génétique), Mutation (génétique), Mâle, Mélanome (anatomopathologie), Mélanome (génétique), Mélanome (traitement médicamenteux), Métastase tumorale, Méthode en double aveugle, Pipéridines (administration et posologie), Pronostic, Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Protéines proto-oncogènes B-raf (génétique), Stade de la tumeur, Sujet âgé, Sujet âgé de 80 ans ou plus, Sulfonamides (administration et posologie), Taux de survie, Tumeurs cutanées (génétique), Tumeurs cutanées (secondaire), Tumeurs cutanées (traitement médicamenteux), Études de suivi.
- MESH :
- administration et posologie : Azétidines, Indoles, Pipéridines, Sulfonamides.
- anatomopathologie : Mélanome.
- génétique : Marqueurs biologiques tumoraux, Mutation, Mélanome, Protéines proto-oncogènes B-raf, Tumeurs cutanées.
- secondaire : Tumeurs cutanées.
- traitement médicamenteux : Mélanome, Tumeurs cutanées.
- usage thérapeutique : Protocoles de polychimiothérapie antinéoplasique.
- Adulte, Adulte d'âge moyen, Femelle, Humains, Jeune adulte, Mâle, Métastase tumorale, Méthode en double aveugle, Pronostic, Stade de la tumeur, Sujet âgé, Sujet âgé de 80 ans ou plus, Taux de survie, Études de suivi.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Azetidines (administration & dosage), Biomarkers, Tumor (genetics), Double-Blind Method, Female, Follow-Up Studies, Humans, Indoles (administration & dosage), Male, Melanoma (drug therapy), Melanoma (genetics), Melanoma (pathology), Middle Aged, Mutation (genetics), Neoplasm Metastasis, Neoplasm Staging, Piperidines (administration & dosage), Prognosis, Proto-Oncogene Proteins B-raf (genetics), Skin Neoplasms (drug therapy), Skin Neoplasms (genetics), Skin Neoplasms (secondary), Sulfonamides (administration & dosage), Survival Rate, Young Adult.
- MESH :
- chemical , administration & dosage : Azetidines, Indoles, Piperidines, Sulfonamides.
- chemical , genetics : Biomarkers, Tumor, Proto-Oncogene Proteins B-raf.
- drug therapy : Melanoma, Skin Neoplasms.
- genetics : Melanoma, Mutation, Skin Neoplasms.
- pathology : Melanoma.
- secondary : Skin Neoplasms.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Adult, Aged, Aged, 80 and over, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Survival Rate, Young Adult.
Abstract
The combination of cobimetinib with vemurafenib improves progression-free survival compared with placebo and vemurafenib in previously untreated patients with BRAF(V600)-mutant advanced melanoma, as previously reported in the coBRIM study. In this Article, we report updated efficacy results, including overall survival and safety after longer follow-up, and selected biomarker correlative studies.
DOI: 10.1016/S1470-2045(16)30122-X
PubMed: 27480103
Affiliations:
- Allemagne, Australie, Espagne, France, Hongrie, Italie, Royaume-Uni, Russie, États-Unis
- Angleterre, Aquitaine, Auvergne-Rhône-Alpes, Bade-Wurtemberg, Californie, District de Tübingen, District fédéral central, Grand Londres, Hongrie centrale, Nouvelle-Aquitaine, Pays de la Loire, Rhône-Alpes, Victoria (État)
- Bordeaux, Budapest, Londres, Lyon, Melbourne, Moscou, Nantes, Tübingen
- Université de Melbourne
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001892
- to stream PubMed, to step Curation: 001869
- to stream PubMed, to step Checkpoint: 001869
- to stream Ncbi, to step Merge: 003930
- to stream Ncbi, to step Curation: 003930
- to stream Ncbi, to step Checkpoint: 003930
- to stream Main, to step Merge: 002212
- to stream Main, to step Curation: 002213
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.</title><author><name sortKey="Ascierto, Paolo A" sort="Ascierto, Paolo A" uniqKey="Ascierto P" first="Paolo A" last="Ascierto">Paolo A. Ascierto</name><affiliation wicri:level="1"><nlm:affiliation>Istituto Nazionale Tumori Fondazione G Pascale, Naples, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Istituto Nazionale Tumori Fondazione G Pascale, Naples</wicri:regionArea><wicri:noRegion>Naples</wicri:noRegion></affiliation></author><author><name sortKey="Mcarthur, Grant A" sort="Mcarthur, Grant A" uniqKey="Mcarthur G" first="Grant A" last="Mcarthur">Grant A. Mcarthur</name><affiliation wicri:level="4"><nlm:affiliation>Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; University of Melbourne, Parkville, VIC, Australia. Electronic address: grant.mcarthur@petermac.org.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; University of Melbourne, Parkville, VIC</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Dreno, Brigitte" sort="Dreno, Brigitte" uniqKey="Dreno B" first="Brigitte" last="Dréno">Brigitte Dréno</name><affiliation wicri:level="3"><nlm:affiliation>Nantes University, Nantes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Nantes University, Nantes</wicri:regionArea><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Atkinson, Victoria" sort="Atkinson, Victoria" uniqKey="Atkinson V" first="Victoria" last="Atkinson">Victoria Atkinson</name><affiliation wicri:level="1"><nlm:affiliation>Princess Alexandra Hospital, Woolloongabba, QLD, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Princess Alexandra Hospital, Woolloongabba, QLD</wicri:regionArea><wicri:noRegion>QLD</wicri:noRegion></affiliation></author><author><name sortKey="Liszkay, Gabrielle" sort="Liszkay, Gabrielle" uniqKey="Liszkay G" first="Gabrielle" last="Liszkay">Gabrielle Liszkay</name><affiliation wicri:level="3"><nlm:affiliation>National Institute of Oncology, Budapest, Hungary.</nlm:affiliation><country xml:lang="fr">Hongrie</country><wicri:regionArea>National Institute of Oncology, Budapest</wicri:regionArea><placeName><settlement type="city">Budapest</settlement><region nuts="2">Hongrie centrale</region></placeName></affiliation></author><author><name sortKey="Di Giacomo, Anna Maria" sort="Di Giacomo, Anna Maria" uniqKey="Di Giacomo A" first="Anna Maria" last="Di Giacomo">Anna Maria Di Giacomo</name><affiliation wicri:level="1"><nlm:affiliation>Azienda Ospedaliera Universitaria Senese, Siena, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Azienda Ospedaliera Universitaria Senese, Siena</wicri:regionArea><wicri:noRegion>Siena</wicri:noRegion></affiliation></author><author><name sortKey="Mandala, Mario" sort="Mandala, Mario" uniqKey="Mandala M" first="Mario" last="Mandalà">Mario Mandalà</name><affiliation wicri:level="1"><nlm:affiliation>Papa Giovanni XXIII Hospital, Bergamo, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Papa Giovanni XXIII Hospital, Bergamo</wicri:regionArea><wicri:noRegion>Bergamo</wicri:noRegion></affiliation></author><author><name sortKey="Demidov, Lev" sort="Demidov, Lev" uniqKey="Demidov L" first="Lev" last="Demidov">Lev Demidov</name><affiliation wicri:level="3"><nlm:affiliation>N N Blokhin Russian Cancer Research Center, Moscow, Russia.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>N N Blokhin Russian Cancer Research Center, Moscow</wicri:regionArea><placeName><settlement type="city">Moscou</settlement><region>District fédéral central</region></placeName></affiliation></author><author><name sortKey="Stroyakovskiy, Daniil" sort="Stroyakovskiy, Daniil" uniqKey="Stroyakovskiy D" first="Daniil" last="Stroyakovskiy">Daniil Stroyakovskiy</name><affiliation wicri:level="1"><nlm:affiliation>Moscow City Oncology Hospital 62, Krasnogorsk, Russia.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>Moscow City Oncology Hospital 62, Krasnogorsk</wicri:regionArea><wicri:noRegion>Krasnogorsk</wicri:noRegion></affiliation></author><author><name sortKey="Thomas, Luc" sort="Thomas, Luc" uniqKey="Thomas L" first="Luc" last="Thomas">Luc Thomas</name><affiliation wicri:level="3"><nlm:affiliation>Centre Hospitalier Lyon Sud, Lyon 1 University, Lyon, France; Lyons Cancer Research Center, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre Hospitalier Lyon Sud, Lyon 1 University, Lyon, France; Lyons Cancer Research Center, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="De La Cruz Merino, Luis" sort="De La Cruz Merino, Luis" uniqKey="De La Cruz Merino L" first="Luis" last="De La Cruz-Merino">Luis De La Cruz-Merino</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Universitario Virgen Macarena, Seville, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario Virgen Macarena, Seville</wicri:regionArea><wicri:noRegion>Seville</wicri:noRegion></affiliation></author><author><name sortKey="Dutriaux, Caroline" sort="Dutriaux, Caroline" uniqKey="Dutriaux C" first="Caroline" last="Dutriaux">Caroline Dutriaux</name><affiliation wicri:level="3"><nlm:affiliation>Hôpital Saint André, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Saint André, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Garbe, Claus" sort="Garbe, Claus" uniqKey="Garbe C" first="Claus" last="Garbe">Claus Garbe</name><affiliation wicri:level="3"><nlm:affiliation>University of Tübingen, Tübingen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>University of Tübingen, Tübingen</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Tübingen</region><settlement type="city">Tübingen</settlement></placeName></affiliation></author><author><name sortKey="Yan, Yibing" sort="Yan, Yibing" uniqKey="Yan Y" first="Yibing" last="Yan">Yibing Yan</name><affiliation wicri:level="2"><nlm:affiliation>Genentech Inc, South San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Genentech Inc, South San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Wongchenko, Matthew" sort="Wongchenko, Matthew" uniqKey="Wongchenko M" first="Matthew" last="Wongchenko">Matthew Wongchenko</name><affiliation wicri:level="2"><nlm:affiliation>Genentech Inc, South San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Genentech Inc, South San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Chang, Ilsung" sort="Chang, Ilsung" uniqKey="Chang I" first="Ilsung" last="Chang">Ilsung Chang</name><affiliation wicri:level="2"><nlm:affiliation>Genentech Inc, South San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Genentech Inc, South San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Hsu, Jessie J" sort="Hsu, Jessie J" uniqKey="Hsu J" first="Jessie J" last="Hsu">Jessie J. Hsu</name><affiliation wicri:level="2"><nlm:affiliation>Genentech Inc, South San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Genentech Inc, South San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Koralek, Daniel O" sort="Koralek, Daniel O" uniqKey="Koralek D" first="Daniel O" last="Koralek">Daniel O. Koralek</name><affiliation wicri:level="2"><nlm:affiliation>Genentech Inc, South San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Genentech Inc, South San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Rooney, Isabelle" sort="Rooney, Isabelle" uniqKey="Rooney I" first="Isabelle" last="Rooney">Isabelle Rooney</name><affiliation wicri:level="2"><nlm:affiliation>Genentech Inc, South San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Genentech Inc, South San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Ribas, Antoni" sort="Ribas, Antoni" uniqKey="Ribas A" first="Antoni" last="Ribas">Antoni Ribas</name><affiliation wicri:level="2"><nlm:affiliation>Jonsson Comprehensive Cancer Center at University of California, Los Angeles, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Jonsson Comprehensive Cancer Center at University of California, Los Angeles, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Larkin, James" sort="Larkin, James" uniqKey="Larkin J" first="James" last="Larkin">James Larkin</name><affiliation wicri:level="3"><nlm:affiliation>Royal Marsden NHS Foundation Trust, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Royal Marsden NHS Foundation Trust, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27480103</idno><idno type="pmid">27480103</idno><idno type="doi">10.1016/S1470-2045(16)30122-X</idno><idno type="wicri:Area/PubMed/Corpus">001892</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001892</idno><idno type="wicri:Area/PubMed/Curation">001869</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001869</idno><idno type="wicri:Area/PubMed/Checkpoint">001869</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001869</idno><idno type="wicri:Area/Ncbi/Merge">003930</idno><idno type="wicri:Area/Ncbi/Curation">003930</idno><idno type="wicri:Area/Ncbi/Checkpoint">003930</idno><idno type="wicri:Area/Main/Merge">002212</idno><idno type="wicri:Area/Main/Curation">002213</idno><idno type="wicri:Area/Main/Exploration">002213</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.</title><author><name sortKey="Ascierto, Paolo A" sort="Ascierto, Paolo A" uniqKey="Ascierto P" first="Paolo A" last="Ascierto">Paolo A. Ascierto</name><affiliation wicri:level="1"><nlm:affiliation>Istituto Nazionale Tumori Fondazione G Pascale, Naples, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Istituto Nazionale Tumori Fondazione G Pascale, Naples</wicri:regionArea><wicri:noRegion>Naples</wicri:noRegion></affiliation></author><author><name sortKey="Mcarthur, Grant A" sort="Mcarthur, Grant A" uniqKey="Mcarthur G" first="Grant A" last="Mcarthur">Grant A. Mcarthur</name><affiliation wicri:level="4"><nlm:affiliation>Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; University of Melbourne, Parkville, VIC, Australia. Electronic address: grant.mcarthur@petermac.org.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; University of Melbourne, Parkville, VIC</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Dreno, Brigitte" sort="Dreno, Brigitte" uniqKey="Dreno B" first="Brigitte" last="Dréno">Brigitte Dréno</name><affiliation wicri:level="3"><nlm:affiliation>Nantes University, Nantes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Nantes University, Nantes</wicri:regionArea><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Atkinson, Victoria" sort="Atkinson, Victoria" uniqKey="Atkinson V" first="Victoria" last="Atkinson">Victoria Atkinson</name><affiliation wicri:level="1"><nlm:affiliation>Princess Alexandra Hospital, Woolloongabba, QLD, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Princess Alexandra Hospital, Woolloongabba, QLD</wicri:regionArea><wicri:noRegion>QLD</wicri:noRegion></affiliation></author><author><name sortKey="Liszkay, Gabrielle" sort="Liszkay, Gabrielle" uniqKey="Liszkay G" first="Gabrielle" last="Liszkay">Gabrielle Liszkay</name><affiliation wicri:level="3"><nlm:affiliation>National Institute of Oncology, Budapest, Hungary.</nlm:affiliation><country xml:lang="fr">Hongrie</country><wicri:regionArea>National Institute of Oncology, Budapest</wicri:regionArea><placeName><settlement type="city">Budapest</settlement><region nuts="2">Hongrie centrale</region></placeName></affiliation></author><author><name sortKey="Di Giacomo, Anna Maria" sort="Di Giacomo, Anna Maria" uniqKey="Di Giacomo A" first="Anna Maria" last="Di Giacomo">Anna Maria Di Giacomo</name><affiliation wicri:level="1"><nlm:affiliation>Azienda Ospedaliera Universitaria Senese, Siena, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Azienda Ospedaliera Universitaria Senese, Siena</wicri:regionArea><wicri:noRegion>Siena</wicri:noRegion></affiliation></author><author><name sortKey="Mandala, Mario" sort="Mandala, Mario" uniqKey="Mandala M" first="Mario" last="Mandalà">Mario Mandalà</name><affiliation wicri:level="1"><nlm:affiliation>Papa Giovanni XXIII Hospital, Bergamo, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Papa Giovanni XXIII Hospital, Bergamo</wicri:regionArea><wicri:noRegion>Bergamo</wicri:noRegion></affiliation></author><author><name sortKey="Demidov, Lev" sort="Demidov, Lev" uniqKey="Demidov L" first="Lev" last="Demidov">Lev Demidov</name><affiliation wicri:level="3"><nlm:affiliation>N N Blokhin Russian Cancer Research Center, Moscow, Russia.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>N N Blokhin Russian Cancer Research Center, Moscow</wicri:regionArea><placeName><settlement type="city">Moscou</settlement><region>District fédéral central</region></placeName></affiliation></author><author><name sortKey="Stroyakovskiy, Daniil" sort="Stroyakovskiy, Daniil" uniqKey="Stroyakovskiy D" first="Daniil" last="Stroyakovskiy">Daniil Stroyakovskiy</name><affiliation wicri:level="1"><nlm:affiliation>Moscow City Oncology Hospital 62, Krasnogorsk, Russia.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>Moscow City Oncology Hospital 62, Krasnogorsk</wicri:regionArea><wicri:noRegion>Krasnogorsk</wicri:noRegion></affiliation></author><author><name sortKey="Thomas, Luc" sort="Thomas, Luc" uniqKey="Thomas L" first="Luc" last="Thomas">Luc Thomas</name><affiliation wicri:level="3"><nlm:affiliation>Centre Hospitalier Lyon Sud, Lyon 1 University, Lyon, France; Lyons Cancer Research Center, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre Hospitalier Lyon Sud, Lyon 1 University, Lyon, France; Lyons Cancer Research Center, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="De La Cruz Merino, Luis" sort="De La Cruz Merino, Luis" uniqKey="De La Cruz Merino L" first="Luis" last="De La Cruz-Merino">Luis De La Cruz-Merino</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Universitario Virgen Macarena, Seville, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario Virgen Macarena, Seville</wicri:regionArea><wicri:noRegion>Seville</wicri:noRegion></affiliation></author><author><name sortKey="Dutriaux, Caroline" sort="Dutriaux, Caroline" uniqKey="Dutriaux C" first="Caroline" last="Dutriaux">Caroline Dutriaux</name><affiliation wicri:level="3"><nlm:affiliation>Hôpital Saint André, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Saint André, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Garbe, Claus" sort="Garbe, Claus" uniqKey="Garbe C" first="Claus" last="Garbe">Claus Garbe</name><affiliation wicri:level="3"><nlm:affiliation>University of Tübingen, Tübingen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>University of Tübingen, Tübingen</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Tübingen</region><settlement type="city">Tübingen</settlement></placeName></affiliation></author><author><name sortKey="Yan, Yibing" sort="Yan, Yibing" uniqKey="Yan Y" first="Yibing" last="Yan">Yibing Yan</name><affiliation wicri:level="2"><nlm:affiliation>Genentech Inc, South San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Genentech Inc, South San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Wongchenko, Matthew" sort="Wongchenko, Matthew" uniqKey="Wongchenko M" first="Matthew" last="Wongchenko">Matthew Wongchenko</name><affiliation wicri:level="2"><nlm:affiliation>Genentech Inc, South San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Genentech Inc, South San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Chang, Ilsung" sort="Chang, Ilsung" uniqKey="Chang I" first="Ilsung" last="Chang">Ilsung Chang</name><affiliation wicri:level="2"><nlm:affiliation>Genentech Inc, South San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Genentech Inc, South San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Hsu, Jessie J" sort="Hsu, Jessie J" uniqKey="Hsu J" first="Jessie J" last="Hsu">Jessie J. Hsu</name><affiliation wicri:level="2"><nlm:affiliation>Genentech Inc, South San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Genentech Inc, South San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Koralek, Daniel O" sort="Koralek, Daniel O" uniqKey="Koralek D" first="Daniel O" last="Koralek">Daniel O. Koralek</name><affiliation wicri:level="2"><nlm:affiliation>Genentech Inc, South San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Genentech Inc, South San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Rooney, Isabelle" sort="Rooney, Isabelle" uniqKey="Rooney I" first="Isabelle" last="Rooney">Isabelle Rooney</name><affiliation wicri:level="2"><nlm:affiliation>Genentech Inc, South San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Genentech Inc, South San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Ribas, Antoni" sort="Ribas, Antoni" uniqKey="Ribas A" first="Antoni" last="Ribas">Antoni Ribas</name><affiliation wicri:level="2"><nlm:affiliation>Jonsson Comprehensive Cancer Center at University of California, Los Angeles, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Jonsson Comprehensive Cancer Center at University of California, Los Angeles, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Larkin, James" sort="Larkin, James" uniqKey="Larkin J" first="James" last="Larkin">James Larkin</name><affiliation wicri:level="3"><nlm:affiliation>Royal Marsden NHS Foundation Trust, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Royal Marsden NHS Foundation Trust, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></analytic><series><title level="j">The Lancet. Oncology</title><idno type="eISSN">1474-5488</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Azetidines (administration & dosage)</term><term>Biomarkers, Tumor (genetics)</term><term>Double-Blind Method</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Indoles (administration & dosage)</term><term>Male</term><term>Melanoma (drug therapy)</term><term>Melanoma (genetics)</term><term>Melanoma (pathology)</term><term>Middle Aged</term><term>Mutation (genetics)</term><term>Neoplasm Metastasis</term><term>Neoplasm Staging</term><term>Piperidines (administration & dosage)</term><term>Prognosis</term><term>Proto-Oncogene Proteins B-raf (genetics)</term><term>Skin Neoplasms (drug therapy)</term><term>Skin Neoplasms (genetics)</term><term>Skin Neoplasms (secondary)</term><term>Sulfonamides (administration & dosage)</term><term>Survival Rate</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Azétidines (administration et posologie)</term><term>Femelle</term><term>Humains</term><term>Indoles (administration et posologie)</term><term>Jeune adulte</term><term>Marqueurs biologiques tumoraux (génétique)</term><term>Mutation (génétique)</term><term>Mâle</term><term>Mélanome (anatomopathologie)</term><term>Mélanome (génétique)</term><term>Mélanome (traitement médicamenteux)</term><term>Métastase tumorale</term><term>Méthode en double aveugle</term><term>Pipéridines (administration et posologie)</term><term>Pronostic</term><term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term><term>Protéines proto-oncogènes B-raf (génétique)</term><term>Stade de la tumeur</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Sulfonamides (administration et posologie)</term><term>Taux de survie</term><term>Tumeurs cutanées (génétique)</term><term>Tumeurs cutanées (secondaire)</term><term>Tumeurs cutanées (traitement médicamenteux)</term><term>Études de suivi</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Azetidines</term><term>Indoles</term><term>Piperidines</term><term>Sulfonamides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Biomarkers, Tumor</term><term>Proto-Oncogene Proteins B-raf</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Azétidines</term><term>Indoles</term><term>Pipéridines</term><term>Sulfonamides</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Mélanome</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Melanoma</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Melanoma</term><term>Mutation</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Marqueurs biologiques tumoraux</term><term>Mutation</term><term>Mélanome</term><term>Protéines proto-oncogènes B-raf</term><term>Tumeurs cutanées</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Melanoma</term></keywords><keywords scheme="MESH" qualifier="secondaire" xml:lang="fr"><term>Tumeurs cutanées</term></keywords><keywords scheme="MESH" qualifier="secondary" xml:lang="en"><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Mélanome</term><term>Tumeurs cutanées</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Double-Blind Method</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Metastasis</term><term>Neoplasm Staging</term><term>Prognosis</term><term>Survival Rate</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Métastase tumorale</term><term>Méthode en double aveugle</term><term>Pronostic</term><term>Stade de la tumeur</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Taux de survie</term><term>Études de suivi</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The combination of cobimetinib with vemurafenib improves progression-free survival compared with placebo and vemurafenib in previously untreated patients with BRAF(V600)-mutant advanced melanoma, as previously reported in the coBRIM study. In this Article, we report updated efficacy results, including overall survival and safety after longer follow-up, and selected biomarker correlative studies.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Espagne</li><li>France</li><li>Hongrie</li><li>Italie</li><li>Royaume-Uni</li><li>Russie</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Aquitaine</li><li>Auvergne-Rhône-Alpes</li><li>Bade-Wurtemberg</li><li>Californie</li><li>District de Tübingen</li><li>District fédéral central</li><li>Grand Londres</li><li>Hongrie centrale</li><li>Nouvelle-Aquitaine</li><li>Pays de la Loire</li><li>Rhône-Alpes</li><li>Victoria (État)</li></region><settlement><li>Bordeaux</li><li>Budapest</li><li>Londres</li><li>Lyon</li><li>Melbourne</li><li>Moscou</li><li>Nantes</li><li>Tübingen</li></settlement><orgName><li>Université de Melbourne</li></orgName></list><tree><country name="Italie"><noRegion><name sortKey="Ascierto, Paolo A" sort="Ascierto, Paolo A" uniqKey="Ascierto P" first="Paolo A" last="Ascierto">Paolo A. Ascierto</name></noRegion><name sortKey="Di Giacomo, Anna Maria" sort="Di Giacomo, Anna Maria" uniqKey="Di Giacomo A" first="Anna Maria" last="Di Giacomo">Anna Maria Di Giacomo</name><name sortKey="Mandala, Mario" sort="Mandala, Mario" uniqKey="Mandala M" first="Mario" last="Mandalà">Mario Mandalà</name></country><country name="Australie"><region name="Victoria (État)"><name sortKey="Mcarthur, Grant A" sort="Mcarthur, Grant A" uniqKey="Mcarthur G" first="Grant A" last="Mcarthur">Grant A. Mcarthur</name></region><name sortKey="Atkinson, Victoria" sort="Atkinson, Victoria" uniqKey="Atkinson V" first="Victoria" last="Atkinson">Victoria Atkinson</name></country><country name="France"><region name="Pays de la Loire"><name sortKey="Dreno, Brigitte" sort="Dreno, Brigitte" uniqKey="Dreno B" first="Brigitte" last="Dréno">Brigitte Dréno</name></region><name sortKey="Dutriaux, Caroline" sort="Dutriaux, Caroline" uniqKey="Dutriaux C" first="Caroline" last="Dutriaux">Caroline Dutriaux</name><name sortKey="Thomas, Luc" sort="Thomas, Luc" uniqKey="Thomas L" first="Luc" last="Thomas">Luc Thomas</name></country><country name="Hongrie"><region name="Hongrie centrale"><name sortKey="Liszkay, Gabrielle" sort="Liszkay, Gabrielle" uniqKey="Liszkay G" first="Gabrielle" last="Liszkay">Gabrielle Liszkay</name></region></country><country name="Russie"><region name="District fédéral central"><name sortKey="Demidov, Lev" sort="Demidov, Lev" uniqKey="Demidov L" first="Lev" last="Demidov">Lev Demidov</name></region><name sortKey="Stroyakovskiy, Daniil" sort="Stroyakovskiy, Daniil" uniqKey="Stroyakovskiy D" first="Daniil" last="Stroyakovskiy">Daniil Stroyakovskiy</name></country><country name="Espagne"><noRegion><name sortKey="De La Cruz Merino, Luis" sort="De La Cruz Merino, Luis" uniqKey="De La Cruz Merino L" first="Luis" last="De La Cruz-Merino">Luis De La Cruz-Merino</name></noRegion></country><country name="Allemagne"><region name="Bade-Wurtemberg"><name sortKey="Garbe, Claus" sort="Garbe, Claus" uniqKey="Garbe C" first="Claus" last="Garbe">Claus Garbe</name></region></country><country name="États-Unis"><region name="Californie"><name sortKey="Yan, Yibing" sort="Yan, Yibing" uniqKey="Yan Y" first="Yibing" last="Yan">Yibing Yan</name></region><name sortKey="Chang, Ilsung" sort="Chang, Ilsung" uniqKey="Chang I" first="Ilsung" last="Chang">Ilsung Chang</name><name sortKey="Hsu, Jessie J" sort="Hsu, Jessie J" uniqKey="Hsu J" first="Jessie J" last="Hsu">Jessie J. Hsu</name><name sortKey="Koralek, Daniel O" sort="Koralek, Daniel O" uniqKey="Koralek D" first="Daniel O" last="Koralek">Daniel O. Koralek</name><name sortKey="Ribas, Antoni" sort="Ribas, Antoni" uniqKey="Ribas A" first="Antoni" last="Ribas">Antoni Ribas</name><name sortKey="Rooney, Isabelle" sort="Rooney, Isabelle" uniqKey="Rooney I" first="Isabelle" last="Rooney">Isabelle Rooney</name><name sortKey="Wongchenko, Matthew" sort="Wongchenko, Matthew" uniqKey="Wongchenko M" first="Matthew" last="Wongchenko">Matthew Wongchenko</name></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Larkin, James" sort="Larkin, James" uniqKey="Larkin J" first="James" last="Larkin">James Larkin</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002213 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002213 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27480103
|texte= Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27480103" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |